Development of New Diagnostic Tools in Capsule Endoscopy
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Nov 21, 2023
Trial Information
Current as of November 11, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how to improve the way doctors use capsule endoscopy to diagnose bowel diseases such as Crohn's disease, celiac disease, chronic diarrhea, and tumors. Capsule endoscopy is a procedure where patients swallow a small capsule that takes pictures of their intestines. The goal of this trial is to use these images and videos to train artificial intelligence (AI) tools that can help doctors read the results faster and more accurately.
To participate in this study, you need to be a patient who is already scheduled for a capsule endoscopy as part of your routine care. You will be asked to allow your images and videos from the procedure to be used for research purposes. If you agree, you can expect that your data will help improve future diagnoses for others with similar conditions. The trial is currently looking for participants of all ages and genders.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • - Any patient in whom a capsule endoscopy examination is performed as part of routine care.
- Exclusion Criteria:
- • - Opposition to the use of images and videos from daily, routine care for research purposes.
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Paris, France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported